Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Wednesday, May 17, 2017

Relapsing-remitting MS: Alemtuzumab boosts outcomes for black patients


                                                                  
  
Click here to receive MS news via e-mail

May 6, 2017

Alemtuzumab improves long-term clinical and radiological outcomes in black patients with relapsing-remitting multiple sclerosis, according to data presented at the 69th Annual Meeting of the American Academy of Neurology in Boston, MA.


The new findings were seen in a small cohort of patients enrolled in phase III studies comparing alemtuzumab with subcutaneous interferon beta-1a (SC IFNB-1a), all of whom had relapsing-remitting multiple sclerosis (RRMS) and were either treatment-naïve at enrollment or had responded inadequately to prior therapy.

Importantly, the results in black patients were on a par with those previously reported in the overall study population, said principal investigator Dr. Annette Okai, from the Multiple Sclerosis Treatment Center of Dallas in Texas.
Black patients typically have more severe MS than white patients, characterized by more rapid disability accumulation, greater MRI lesion volumes, increased risk for secondary progression, accelerated retinal nerve fiber layer and ganglion cell/inner plexiform layer thinning, and the potential for a poorer response to disease-modifying therapies (DMTs).


READ MORE


MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
MS Views and News provides beneficial information for those affected by Multiple Sclerosis. Join us by registering here: www.register.msviewsandnews.org 

No comments: